Telix Pharmaceuticals (TLX) reported Q1 unaudited revenue Tuesday of about $186 million, up from $115 million a year earlier.
Two analysts polled by FactSet expected $145.3 million.
For 2025, the biotech company reaffirmed its previous revenue guidance of $770 million to $800 million.
Analysts polled by FactSet expect $770 million.